phrykt

Entrada Therapeutics, Inc. (TRDA): who owns it and who trades it

As of Nov 16, 2026, TRDA insiders reported 26 open-market sales worth $6.7M and 5 purchases worth $291K in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was MPM BioVentures 2018 GP LLC (10% owner), with $1.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Entrada Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TRDA

129 funds and institutions reported TRDA shares worth $219M at the end of Q2 2026, about 76% of the company. The largest holder is Baker Bros. Advisors LP with 13.1%.

Funds and institutions (13F) 76%Everyone else 24%

10 largest owners, by share of the company

Baker Bros. Advisors LP13.1%
5AM Venture Management, LLC10.4%
BlackRock, Inc.6.7%
Merck & Co., Inc.4.5%
Vanguard Capital Management LLC3.3%
Mpm Bioimpact LLC3.2%
TCG Crossover Management, LLC2.7%
Wellington Management Group LLP2.5%
Millennium Management LLC2.0%
StepStone Group LP2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP5.07M13.07%$37.3MNo change
5AM Venture Management, LLC4.06M10.45%$29.9MNo change
BlackRock, Inc.2.58M6.65%$19M+10%
Merck & Co., Inc.1.74M4.48%$12.8M–
Vanguard Capital Management LLC1.27M3.27%$9.3M+1%
Mpm Bioimpact LLC1.25M3.23%$9.2M–
TCG Crossover Management, LLC1.06M2.73%$7.8M-54%
Wellington Management Group LLP954,4192.46%$7M-8%
Millennium Management LLC763,9591.97%$5.6M+47%
StepStone Group LP761,2771.96%$5.6MNo change
Geode Capital Management, LLC717,4301.85%$5.3M+8%
AQR Capital Management LLC699,5371.80%$5.1M+780%
Nantahala Capital Management, LLC601,1501.55%$4.4M+277%
State Street Corp596,6771.54%$4.4M+12%
T. Rowe Price Associates542,3161.40%$4M+3%
JPMorgan Chase & Co496,4571.28%$3.8M–
Acadian Asset Management LLC400,8621.03%$2.9M+20%
Citadel Advisors LLC394,3231.02%$2.9M+83%
Dimensional Fund Advisors LP376,1360.97%$2.8M+16%
Northern Trust Corp309,9420.80%$2.3M+32%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TRDA insiders reported $291K of open-market purchases and $6.7M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$291K
5 trades, 2 people
Sales, 12 months
$6.7M
26 trades, 8 people
Sales under a 10b5-1 plan
19%
Share of sale value
Latest trade
Sep 9, 2026
Filed Sep 9, 2026

Purchases and sales by month

$2.5M$2.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 9, 2026MPM BioVentures 2018 GP LLC +210% ownerSale28,837$7.13$206KForm 4
Sep 8, 2026MPM BioVentures 2018 GP LLC +210% ownerSale192,500$7.41$1.4MForm 4
Sep 4, 2026MPM BioVentures 2018 GP LLC +210% ownerSale38,500$7.11$274KForm 4
Sep 3, 2026MPM BioVentures 2018 LLC +210% ownerSale32,263$7.17$231KForm 4
Sep 2, 2026MPM BioVentures 2018 LLC +210% ownerSale25,131$7.19$181KForm 4
Sep 1, 2026MPM BioVentures 2018 LLC +210% ownerSale29,088$7.06$205KForm 4
Aug 31, 2026MPM BioVentures 2018 LLC +210% ownerSale44,259$6.99$309KForm 4
Aug 28, 2026MPM BioVentures 2018 LLC +210% ownerSale3,733$7.01$26.2KForm 4
Aug 27, 2026MPM BioVentures 2018 LLC +210% ownerSale38,922$7.20$280KForm 4
Aug 26, 2026Todd Foley +910% ownerSale14,569$7.06$103KForm 4
Aug 25, 2026Todd Foley +910% ownerSale26,522$7.54$200KForm 4
Aug 24, 2026Todd Foley +910% ownerSale21,623$7.34$159KForm 4
Aug 10, 2026Kush ParmarDirectorSale92,444$7.00$647KForm 4
Aug 7, 2026Kush ParmarDirectorSale52,317$6.85$358KForm 4
Aug 6, 2026Kush ParmarDirectorSale10,494$7.00$73.5KForm 4
Jul 31, 2026Scott M Rocklage +510% ownerSale1,718$6.85$11.8KForm 4
Jul 30, 2026Scott M Rocklage +510% ownerSale114,756$6.93$795KForm 4
May 20, 2026Bernhardt G ZeiherDirectorPurchase5,000$5.86$29.3KForm 4
May 4, 2026Natarajan SethuramanPresidentSale plan25,907$15.39$399KForm 4
May 4, 2026Nathan J DowdenPresidentSale plan15,000$15.33$230KForm 4
Apr 1, 2026Kory James WentworthCFOSale plan2,500$12.95$32.4KForm 4
Mar 10, 2026Nathan J DowdenPresidentSale plan11,894$13.05$155KForm 4
Mar 10, 2026Kory James WentworthCFOSale plan11,388$13.02$148KForm 4
Mar 9, 2026Nathan J DowdenPresidentSale plan3,116$13.02$40.6KForm 4
Mar 9, 2026Kory James WentworthCFOSale plan5,089$13.00$66.2KForm 4
Mar 4, 2026Kory James WentworthCFOSale plan7,988$12.25$97.9KForm 4
Nov 21, 2025Kory James WentworthCFOSale plan8,910$9.98$88.9KForm 4
Nov 20, 2025Felix Baker +310% ownerPurchase13,082$9.07$119KForm 4
Nov 20, 2025Felix Baker +310% ownerPurchase1,186$9.07$10.8KForm 4
Nov 20, 2025Felix Baker +310% ownerPurchase13,386$9.07$121KForm 4
Nov 20, 2025Felix Baker +310% ownerPurchase1,213$9.07$11KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
MPM BioVentures 2018 GP LLC10% owner–$1.9MSep 9, 2026
MPM BioVentures 2018 LLC10% owner–$1.2MSep 3, 2026
Kush ParmarDirector–$1.1MAug 10, 2026
Scott M Rocklage10% owner–$807KJul 31, 2026
Todd Foley10% owner–$462KAug 26, 2026
Kory James WentworthChief Financial Officer–$434KApr 1, 2026
Nathan J DowdenPresident & COO–$426KMay 4, 2026
Natarajan SethuramanPresident, Research & Develop.–$399KMay 4, 2026
Felix Baker10% owner$262K–Nov 20, 2025
Bernhardt G ZeiherDirector$29.3K–May 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TRDA short interest

Moderate short interest. 7.2% of TRDA shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 86%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.81M TRDA shares were sold short, 7.2% of the shares outstanding, down 14.2% from the report before. At the average daily volume of 408,246 shares, buying them all back would take about 6.9 trading days (days to cover).

Shares short, % of all shares

7.21%May 15Oct 309.08%

Days to cover

6.9May 15Oct 3012.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.81M7.21%-14%408,2466.9
Oct 15, 20263.27M8.40%+9%380,6058.6
Sep 30, 20262.99M7.68%+9%303,1699.9
Sep 15, 20262.74M7.05%+17%340,4158.1
Aug 31, 20262.35M6.02%-1%219,45110.7
Aug 14, 20262.37M6.08%+10%384,8546.2
Jul 31, 20262.14M5.51%-4%494,7474.3
Jul 15, 20262.23M5.75%+6%356,5826.3
Jun 30, 20262.11M5.44%+10%360,8095.8
Jun 15, 20261.91M4.93%+11%239,1288.0
May 29, 20261.73M4.45%+15%386,6264.5
May 15, 20261.51M3.88%+51%972,0651.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Entrada Therapeutics company events

Entrada Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 14, 2026AnnouncementThe Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jun 10, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  5. May 19, 2026AnnouncementShared information with investors. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Feb 26, 2026ResultsReleased financial results. Filing
  8. Jan 8, 2026AnnouncementThe Company reported its progress across its portfolio of RNA-based therapeutics for the treatment of neuromuscular and ocular diseases. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Entrada Therapeutics financials

Famous investors that hold TRDA

4 of the 50 well-known investors we track reported holding TRDA in their latest 13F filing. The largest position is Ken Griffin's, worth $2.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026461,737$2.9M0.0%+17%
Israel Englander · Millennium ManagementQ3 2026344,603$2.2M0.0%-55%
Jim Simons · Renaissance TechnologiesQ3 2026199,200$1.3M0.0%+4%
Steve Cohen · Point72 Asset ManagementQ3 2026101,727$646K0.0%+257%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Entrada Therapeutics, Inc. (TRDA) stock

Who owns the most TRDA stock?

The largest reported owner of Entrada Therapeutics, Inc. (TRDA) is Baker Bros. Advisors LP, with 13.1% of the company. In total, 129 funds and institutions reported holding TRDA at the end of Q2 2026, together about 76% of the shares. See the largest owners.

Are TRDA insiders buying or selling?

In the last 12 months, TRDA insiders reported 5 open-market purchases worth $291K and 26 sales worth $6.7M. The latest trade was on Sep 9, 2026. See every trade.

What is the short interest in TRDA?

As of Oct 30, 2026, 2.81M TRDA shares were sold short, 7.2% of the shares outstanding, down 14.2% from the report before. At the average daily volume of 408,246 shares, buying them all back would take about 6.9 trading days (days to cover). See the history.

Which famous investors hold TRDA?

4 of the 50 well-known investors we track reported TRDA in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $2.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.